Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies September 18, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors September 18, 2024
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers September 18, 2024
Scancell and PharmaJet to use Stratis® IM Needle-free delivery System for SCIB1/iSCIB1+ vaccine for Advanced Melanoma September 17, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs in solid tumors through Clinical Development September 10, 2024
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody September 10, 2024
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors September 10, 2024
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA September 10, 2024
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer September 10, 2024
Novartis begins construction of two new radioligand therapy facilities in the US, expanding RLT manufacturing and supply network September 10, 2024
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 + KEYTRUDA in Patients with IO-Resistant HCC, Melanoma, and RCC September 3, 2024
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology September 3, 2024
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib September 3, 2024
CancerVax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment September 3, 2024
Foundation Medicine Collaborates with Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform September 3, 2024
Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer August 27, 2024
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m NSCLC August 27, 2024
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on ADC Drug Candidate Targeting Tissue Factor August 27, 2024
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement for Ph 1/2a Study of SON-1210 + Chemo for the Treatment of Pancreatic Cancer August 22, 2024
Pathos Expands Pipeline With Worldwide License of Ph 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor August 22, 2024
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical August 13, 2024
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers August 13, 2024
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines August 13, 2024
